Log In
person
arGEN-X SE
ARGNF
summarize
2 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Immune Treatment Pharma |
Branded Pharmaceuticals
These companies research, develop, and manufacture patented drugs.
|
1.19B | 93.87% |
| Immune Treatment Pharma |
Pre-Revenue Pharmaceuticals
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
0.08B | 6.13% |
| keyboard_arrow_down |
Immune Treatment Pharma
Branded Pharmaceuticals
|
1.19B | 93.87% |
| keyboard_arrow_right |
These companies research, develop, and manufacture patented drugs.
|
||
| keyboard_arrow_down |
Immune Treatment Pharma
Pre-Revenue Pharmaceuticals
|
0.08B | 6.13% |
| keyboard_arrow_right |
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
||